Average Ratings 0 Ratings
Average Ratings 0 Ratings
Description
Specialty and rare diseases often encompass patient populations that are not clearly defined, including individuals who remain undiagnosed or face misdiagnoses, along with healthcare providers who may lack knowledge about these conditions and their various manifestations, resulting in treatment pathways that are poorly understood. IPM.ai operates as an Insights-as-a-Service (IaaS) firm, dedicated to empowering leading life sciences organizations to gain deeper insights into patient care and enhance the quality of life for those affected through the development, clinical research, and commercialization of therapeutic solutions. By predicting market size, analyzing the competitive landscape, and estimating potential return on investment, companies can optimize their commercialization strategies. Additionally, the platform identifies undiagnosed and misdiagnosed individuals who could benefit from early disease interception and therapeutic measures. It employs statistical models to gauge the prevalence of specific diseases within certain patient populations at any given moment. Furthermore, IPM.ai helps pinpoint physicians who are adept at diagnosing and treating these ideal patients, while also influencing other healthcare providers to enhance overall patient outcomes. This comprehensive approach ultimately aims to bridge the gap in understanding and addressing the needs of those with rare diseases.
Description
IntelliSpace Portal 9.0 is an innovative visualization platform encompassing over 70 clinical applications, providing a cohesive solution that enhances speed and efficiency while boosting diagnostic confidence, particularly in the analysis and monitoring of complex cases. As the global population ages, the prevalence of neurodegenerative diseases continues to escalate, necessitating long-term monitoring for patients with neurological disorders, which can often exhibit subtle brain changes that are difficult to identify. To address these challenges, IntelliSpace Portal 9.0 introduces several new and improved neuro applications, including NeuroQuant®¹, LoBi, and CT Brain Perfusion, all designed for swift, objective, and consistent image assessment. Additionally, with a growing focus on pulmonary health, this platform equips you with a comprehensive suite of tools to seamlessly manage pulmonary disease from initial detection through to ongoing follow-up, ultimately aiming to improve patient outcomes. This integration of neuro and pulmonary features positions IntelliSpace Portal 9.0 as a vital resource in modern medical imaging and diagnostics.
API Access
Has API
API Access
Has API
Integrations
Imorgon
Pricing Details
No price information available.
Free Trial
Free Version
Pricing Details
No price information available.
Free Trial
Free Version
Deployment
Web-Based
On-Premises
iPhone App
iPad App
Android App
Windows
Mac
Linux
Chromebook
Deployment
Web-Based
On-Premises
iPhone App
iPad App
Android App
Windows
Mac
Linux
Chromebook
Customer Support
Business Hours
Live Rep (24/7)
Online Support
Customer Support
Business Hours
Live Rep (24/7)
Online Support
Types of Training
Training Docs
Webinars
Live Training (Online)
In Person
Types of Training
Training Docs
Webinars
Live Training (Online)
In Person
Vendor Details
Company Name
IPM.ai
Country
United States
Website
www.ipm.ai/platform
Vendor Details
Company Name
Philips
Founded
1891
Country
Netherlands
Website
www.usa.philips.com/healthcare/product/HC881072/intellispace-portal-advanced-visualization-solution
Product Features
Product Features
Medical Imaging
Automated Routing
Comparison View
Compliance Management
Data Import / Export
Diagnostic Reporting
Image Analytics
Treatment Planning
Workflow Management
PACS
Comparison View
Data Compression
Diagnostic Reporting
HL7 Support
Image Management
Mobile Access
Non-DICOM Imaging Support
Patient Portal
Referring Physician Portal
Voice Recognition